|
|
| (16 intermediate revisions by 7 users not shown) |
| Line 1: |
Line 1: |
| {{Infobox_Disease |
| | __NOTOC__ |
| Name = {{PAGENAME}} |
| | |
| Image = Pulmon fibrosis.PNG|
| | {{Idiopathic pulmonary fibrosis}} |
| Caption = Extensive lung fibrosis from usual interstitial pneumonitis|
| |
| DiseasesDB = 4815|
| |
| ICD10 = |
| |
| ICD9 = {{ICD9|516.3}} |
| |
| ICDO = |
| |
| OMIM = 178500 |
| |
| MedlinePlus = 000069 |
| |
| MeshID = D011658 |
| |
| }}
| |
| {{Search infobox}}
| |
|
| |
|
| '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' |
|
| |
|
| {{CMG}} | | {{CMG}}; {{AE}} {{AEL}} |
| | |
| {{Editor Help}}
| |
| | |
| ==Overview==
| |
| ''' [[Idiopathic]] Pulmonary Fibrosis (IPF)''', also known as '''Cryptogenic fibrosing alveolitis''', is a chronic progressive interstitial lung disease of unknown etiology. It is one of the two classic interstitial lung diseases, the other being sarcoidosis.<ref name="WMMT">{{cite book |title=The Washington Manual of Medical Therapeutics |last=Cooper |first=Daniel H. |coauthors=Andrew J. Krainik, Sam J. Lubner, Hilary E. L. Reno (eds.)|edition=32nd edition |publisher=Lippincott Williams & Wilkins |pages=276 |isbn=978-0781781251}}</ref>
| |
| | |
| More specifically, '''IPF''' is defined as a distinctive type of ''chronic fibrosing interstitial pneumonia'' of unknown cause associated with a histological pattern of [[usual interstitial pneumonia]] (UIP).<ref name="ATS">{{cite journal |url=http://ajrccm.atsjournals.org/cgi/content/full/161/2/646 |title=Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment |journal=American Journal of Respiratory and Critical Care Medicine |volume=161 |number=2 |month=February |year=2000 |pages=646-664}}</ref>
| |
| | |
| ==Etiology==
| |
| Pulmonary fibrosis has often been called an [[autoimmunity|autoimmune disease]]. However, it is perhaps better characterized as an abnormal and excessive deposition of fibrotic tissue in the pulmonary interstitium with minimal associated inflammation.<ref name="Selman">{{cite journal |last=Selman |first=Moisés |coauthors=Talmadge E. King, Jr.; and Annie Pardo |title=Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy |journal=Annals of Internal Medicine |year=2001 |volume=134 |number=2 |pages=136-51 |url=http://www.annals.org/cgi/content/abstract/134/2/136}}</ref> [[Autoantibodies]], a hallmark of autoimmune diseases, are found in a minority of patients with truly idiopathic pulmonary fibrosis. Moreover, many autoimmune diseases associated with "pulmonary fibrosis", such as scleroderma, are more frequently associated with a related but more inflammatory disease, nonspecific interstitial pneumonitis.<ref>{{cite journal |last=King, Jr. |first=Talmadge E. |title=Centennial review: clinical advances in the diagnosis and therapy of the interstitial lung diseases |url=http://ajrccm.atsjournals.org/cgi/content/full/172/3/268 |journal=American Journal of Respiratory and Critical Care Medicine |year=2005 |volume=172 |number=3 |pages=268-79}}</ref> It is associated with [[smoking]]<ref>{{cite journal |last=Nagai |first=Sonoko |coauthors=Yuma Hoshino, Michio Hayashi, Isao Ito |title=Smoking-related interstitial lung diseases |url=http://www.co-pulmonarymedicine.com/pt/re/copulmonary/abstract.00063198-200009000-00005.htm |journal=Current Opinion in Pulmonary Medicine |volume=6 |issue=5 |pages=415-9 |year=2000 |pmid=10958232}}</ref> and exhibits some dependency on the amount of smoking.<ref>{{cite journal |last=Baumgartner |first=KB |coauthors=Samet JM, Stidley CA, Colby TV, Waldron JA |title=Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis |url= http://ajrccm.atsjournals.org/cgi/content/short/155/1/242 |journal=American Journal of Respiratory and Critical Care Medicine |volume=155 |number=1 |pages=242-248 |year=1997 |pmid=9001319}}</ref>
| |
| | |
| ==Classification==
| |
| '''Idiopathic pulmonary fibrosis''' is a type of [[idiopathic interstitial pneumonia]] (IIP), which in turn is a type (or group) of interstitial lung diseases.<ref name=ATS2>{{cite journal |url=http://ajrccm.atsjournals.org/cgi/content/full/165/2/277 |title=American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias |journal=American Journal of Respiratory and Critical Care Medicine |volume=165 |number=2 |month=January |year=2002 |pages=277-304}}</ref>
| |
| | |
| Idiopathic interstitial pneumonias include:
| |
| * [[idiopathic pulmonary fibrosis]] (IPF) (the most common)
| |
| * [[nonspecific interstitial pneumonia]]
| |
| * [[cryptogenic organizing pneumonia]]
| |
| * [[acute interstitial pneumonia]]
| |
| * respiratory bronchiolitis-associated interstitial lung disease
| |
| * [[desquamative interstitial pneumonia]]
| |
| * [[lymphoid interstitial pneumonia]]
| |
| | |
| ==Clinical features==
| |
| | |
| Idiopathic Pulmonary Fibrosis is slightly more common in males and usually presents in patients greater than 50 years of age. Average survival from time of diagnosis varies between 2.5 and 3.5 years, depending on severity, although some patients live greater than 10 years.<ref name=ATS2/>
| |
| | |
| Symptoms are gradual in onset. The most common are [[dyspnea]] (difficulty breathing), but also include nonproductive [[cough]], [[clubbing]] (a disfigurement of the fingers), and [[crackles]] (crackling sound in lungs during inhalation).<ref name=ATS2/> It should be noted that these features are non-specific and can occur in a spectrum of other pulmonary disorders.
| |
| | |
| The key issue facing clinicians is whether the presenting history, symptoms/signs, radiology, and pulmonary function testing are collectively in keeping with the diagnosis of IPF (which carries the relatively poor prognosis described above) or whether the findings are due to another process. It has long been recognized that patients with interstitial lung disease related to [[asbestos]] exposure, [[drug]]s (particularly [[chemotherapeutic]] agents), a [[connective tissue]] disease, or other diseases may have features that are difficult to distinguish from IPF. Important differential diagnostic considerations include asbestosis; interstitial lung disease related to [[scleroderma]], [[mixed connective tissue disease]], or [[rheumatoid arthritis]]; advanced sarcoidosis, [[hypersensitivity pneumonitis]], or [[Langerhans cell histiocytosis]]; chronic [[pulmonary aspiration]]; radiation-induced fibrosis; as well as previous therapy with [[cyclophosphamide]], [[nitrofurantoin]], [[methotrexate]], and other drugs.
| |
| | |
| When diagnostic uncertainty remains, a surgical lung biopsy may be required to establish the diagnosis. Generally, lung biopsy is only undertaken when it is deemed that its risks are outweighed by the potential benefits of identifying a disease process that may be amenable to a treatment that the patient would likely be able to tolerate.
| |
|
| |
|
| The 2002 American Thoracic Society/European Respiratory Society Consensus Guidelines on the Idiopathic Interstitial Pneumonias have formalized criteria for situations in which it is possible to establish the diagnosis of IPF without a lung biopsy.<ref name=ATS2/>
| | {{SK}} Cryptogenic fibrosing alveolitis, IPF, Diffuse fibrosing alveolitis, Usual interstitial pneumonitis |
|
| |
|
| ==Radiology== | | ==[[Idiopathic pulmonary fibrosis overview|Overview]]== |
| Plain [[chest x-ray]]s reveal decreased lung volumes, typically with prominent reticular interstitial markings near the lung bases and posteriorly. Honeycombing, a pattern of dense fibrosis characterized by multiple tiny air-filled spaces located at the bases of the lungs, is frequently seen in advanced cases. In less severe cases, these changes may not be evident on a plain chest film.
| |
|
| |
|
| High-resolution CT scans of the chest demonstrate a symmetrical pattern of bibasilar, peripheral, and subpleural intralobular septal thickening, fibrotic changes, honeycombing, and traction bronchiectasis and bronchiolectasis. There may be associated ground glass opacity of the lungs but these changes are relatively minor in comparison with the fibrotic changes.<ref>{{cite book |last=Webb |first=W. Richard |coauthors=Nestor L. Müller and David P. Naidich |title=High-resolution CT of the lung |publisher=Lippincott Williams & Wilkins |location=Philadelphia |year=2001 |pages=196 |isbn=978-0781722780}}</ref>
| | ==[[Idiopathic pulmonary fibrosis historical perspective|Historical Perspective]]== |
|
| |
|
| ==Pulmonary function tests== | | ==[[Idiopathic pulmonary fibrosis classification|Classification]]== |
| [[Spirometry]] classically reveals a reduction in the vital capacity with either a proportionate reduction in airflows, or increased airflows for the observed vital capacity. The latter finding reflects the increased lung stiffness (reduced lung compliance) associated with pulmonary fibrosis, which leads to increased lung elastic recoil.<ref>{{cite journal |last=Pellegrino |first=R. |coauthors=Viegi G., Brusasco V., Crapo RO., et al. |title=Interpretative strategies for lung function tests |url=http://erj.ersjournals.com/cgi/content/full/26/5/948?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=26&firstpage=948&resourcetype=HWCIT |journal=European Respiratory Journal |publiser=European Respiratory Society |year=2005 |month=November |volume=26 |number=5 |pages=948-68}}</ref> | |
|
| |
|
| Measurement of static lung volumes using [[body plethysmography]] or other techniques typically reveals reduced lung volumes (restriction). This reflects the difficulty encountered in inflating the fibrotic lungs.
| | ==[[Idiopathic pulmonary fibrosis pathophysiology|Pathophysiology]]== |
|
| |
|
| The diffusing capacity for carbon monoxide (DLCO) is invariably reduced in IPF and may be the only abnormality in mild or early disease. Its impairment underlies the propensity of patients with IPF to exhibit oxygen desaturation with exercise.
| | ==[[Idiopathic pulmonary fibrosis causes|Causes]]== |
|
| |
| ==Histology== | |
| {{main article|Usual interstitial pneumonia}}
| |
|
| |
|
| [[Image:Usual interstitial pneumonia (1).JPG|left|200px|thumb|[[Micrograph]] of usual interstitial pneumonia (UIP). UIP most often represents '''idiopathic pulmonary fibrosis'''. [[H&E stain]]. [[Autopsy]] specimen.]] | | ==[[Idiopathic pulmonary fibrosis differential diagnosis|Differentiating Idiopathic pulmonary fibrosis from other Diseases]]== |
|
| |
|
| [[Histology|Histologic]] specimens for the diagnosis of IPF must be large enough that the pathologist can comment on the underlying lung architecture. | | ==[[Idiopathic pulmonary fibrosis epidemiology and demographics|Epidemiology and Demographics]]== |
|
| |
|
| Small biopsies, such as those obtained via transbronchial lung biopsy (performed during [[bronchoscopy]]) are generally not sufficient for this purpose. Hence, larger biopsies obtained surgically via a thoracotomy or thoracoscopy are usually necessary.<ref name=ATS2/>
| | ==[[Idiopathic pulmonary fibrosis risk factors|Risk Factors]]== |
|
| |
|
| The histological pattern of fibrosis associated with '''IPF''' is referred to as usual interstitial pneumonia (UIP).
| | ==[[Idiopathic pulmonary fibrosis screening|Screening]]== |
|
| |
|
| Although '''UIP''' is required for the diagnosis of '''IPF''', it can be seen in other diseases as well.<ref>{{cite book |title=Robbins and Cotran's Pathological Basis of Disease |edition=7th ed. |first=Vinay |last=Kumar |coauthors=Nelso Fausto and Abul Abbas |year=2005 |publisher=Saunders |isbn=978-0721601878 |pages=729}}</ref>
| | ==[[Idiopathic pulmonary fibrosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| | |
| Key features of UIP include fibroblast foci, a pattern of temporal heterogeneity, dense interstitial fibrosis in a paraseptal and subpleural distribution, and a relatively mild or minor component of interstitial chronic inflammation.<ref name=ATS2/> To help narrow the differential diagnosis, an absence of significant [[granuloma|granulomatous]] inflammation, [[microorganism]]s, [[eosinophil]]s, and [[asbestosis|asbestos bodies]] is required.
| |
|
| |
|
| ==Diagnosis== | | ==Diagnosis== |
| The diagnosis of IPF can be made by demonstrating UIP pattern on lung biopsy in a patient without clinical features suggesting an alternate diagnosis (see clinical features, above). Establishing the diagnosis of IPF without a lung biopsy has been shown to be reliable when expert clinicians and radiologists concur that the presenting features are typical of IPF.<ref>{{cite journal |last=Flaherty |first=Kevin R. |coauthors=Talmadge E. King, Jr., Ganesh Raghu, Joseph P. Lynch, III, Thomas V. Colby, William D. Travis, Barry H. Gross, Ella A. Kazerooni, Galen B. Toews, Qi Long, Susan Murray, Vibha N. Lama, Steven E. Gay, and Fernando J. Martinez |title=Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? |url=http://ajrccm.atsjournals.org/cgi/content/full/170/8/904 |journal=American Journal of Respiratory and Critical Care Medicine |year=2004 |volume=170 |pages=904-10}}</ref> Based on this evidence, the 2002 ATS/ERS Multidisciplinary Consensus Statement on the Idiopathic Interstitial Pneumonias proposes the following criteria for establishing the diagnosis of IPF without a lung biopsy:<ref name=ATS2/>
| | [[Idiopathic pulmonary fibrosis diagnostic study of choice|Diagnostic Study of Choice]] | [[Idiopathic pulmonary fibrosis history and symptoms|History and Symptoms ]] | [[ Idiopathic pulmonary fibrosis physical examination|Physical Examination]] | [[Idiopathic pulmonary fibrosis laboratory findings|Laboratory Findings]] | [[Idiopathic pulmonary fibrosis electrocardiogram|Electrocardiogram]] | [[Idiopathic pulmonary fibrosis chest x ray|Chest X Ray]] | [[Idiopathic pulmonary fibrosis CT|CT]] | [[Idiopathic pulmonary fibrosis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Idiopathic pulmonary fibrosis other imaging findings|Other Imaging Findings]] | [[Idiopathic pulmonary fibrosis other diagnostic studies|Other Diagnostic Studies]] |
| | |
| Major criteria (all 4 required):
| |
| * Exclusion of other known causes of interstitial lung disease (drugs, exposures, connective tissue diseases)
| |
| * Abnormal [[pulmonary function test]]s with evidence of restriction (reduced [[vital capacity]]) and impaired gas exchange (pO<sub>2</sub>, p(A-a)O<sub>2</sub>, [[DLCO]])
| |
| * Bibasilar reticular abnormalities with minimal ground glass on high-resolution CT scans
| |
| * Transbronchial lung biopsy or bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis
| |
| | |
| Minor criteria (3 of 4 required):
| |
| * Age > 50
| |
| * Insidious onset of otherwise unexplained exertional dyspnea
| |
| * Duration of illness > 3 months
| |
| * Bibasilar inspiratory crackles
| |
|
| |
|
| ==Treatment== | | ==Treatment== |
| There is currently no consensus on the treatment of IPF. Hence, none of what follows should be taken as specific advice regarding therapy, as the latter is a decision that must be made on a case-by-case basis in individual patients.<ref name="Walter">{{cite journal | last=Walter | first=N | coauthors=Collard HR, Talmadge E. King, Jr. | title=Current perspectives on the treatment of idiopathic pulmonary fibrosis | journal=Proceedings of the American Thoracic Society | volume=3 | issue=4 | pages=330–338 | publisher=American Thoracic Society | month=June |year=2006 | url=http://pats.atsjournals.org/cgi/content/full/3/4/330 | pmid=16738197 | accessdate=2008-03-05 }}</ref>
| | [[Idiopathic pulmonary fibrosis medical therapy|Medical Therapy]] | [[Idiopathic pulmonary fibrosis surgery |Surgery]] | [[Idiopathic pulmonary fibrosis primary prevention|Primary Prevention]] | [[Idiopathic pulmonary fibrosis secondary prevention|Secondary Prevention]] | [[Idiopathic pulmonary fibrosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Idiopathic pulmonary fibrosis future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| There is a lack of large, randomized placebo-controlled trials of therapy for IPF. Moreover, many of the earlier studies were based on the hypothesis that IPF is an inflammatory disorder, and hence studied anti-inflammatory agents such as [[corticosteroids]]. Another problem has been that studies conducted prior to the more recent classification of idiopathic interstitial pneumonias failed to distinguish IPF/UIP from NSIP in particular. Hence, many patients with arguably more steroid-responsive diseases were included in earlier studies, confounding the interpretation of their results.<ref name="Selman"/>
| | ==Case Studies== |
|
| |
|
| Small early studies demonstrated that the combination of [[prednisone]] with either [[cyclophosphamide]] or [[azathioprine]] over many months had very modest, if any, beneficial effect in IPF, and were associated with substantial adverse effects (predominantly myelotoxicity). Other treatments studied have included [[interferon gamma]]-1b and the antifibrotic agent pirfenidone. While neither drug has been shown to have substantial benefits over time, both are currently being studied in patients with IPF. Finally, the addition of the [[antioxidant]] [[N-acetylcysteine]] to [[prednisone]] and [[azathioprine]] produced a slight benefit in terms of FVC and DLCO over 12 months of follow up. However, the major benefit appeared to be prevention of the myelotoxicity associated with [[azathioprine]].<ref>{{cite journal |last=Demedts |first=Maurits |coauthors=Juergen Behr; Roland Buhl; et al |title=High-dose acetylcysteine in idiopathic pulmonary fibrosis. The IFIGENIA Study |url=http://content.nejm.org/cgi/content/full/353/21/2229 |journal=New England Journal of Medicine |year=2005 |volume=353 |number=21 |pages=2229-2242}}</ref>
| | [[Idiopathic pulmonary fibrosis case study one|Case #1]] |
|
| |
|
| ==References==
| |
| {{reflist|2}}
| |
|
| |
| {{SIB}}
| |
|
| |
| [[Category:Pulmonology]]
| |
| [[Category:Mature chapter]]
| |
| [[Category:Disease state]]
| |
|
| |
|
| | </br> |
| [[de:Idiopathische interstitielle Pneumonie#Idiopathische_pulmonale_Fibrose_.28IPF.29]] | | [[de:Idiopathische interstitielle Pneumonie#Idiopathische_pulmonale_Fibrose_.28IPF.29]] |
| [[es:Fibrosis pulmonar idiopática]] | | [[es:Fibrosis pulmonar idiopática]] |
| Line 116: |
Line 48: |
| {{WikiDoc Help Menu}} | | {{WikiDoc Help Menu}} |
| {{WikiDoc Sources}} | | {{WikiDoc Sources}} |
| | |
| | [[Category:Pulmonology]] |
| | [[Category:Mature chapter]] |
| | [[Category:Disease]] |